维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

12篇 您的检索式：作者名="Auci"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Coma with vertical gaze palsy: rel- evance of angio-CT in acute percheron artery syndrome显示文摘	Godani M Auci A Torri T	2010	Case Rep Neurol2010，2，：	1
	2	The Instability of the Adjusted and Unadjusted Environmental Kuznets Gurves显示文摘	Auci S Becchetti L	2006	Ecological Economics2006，60，：	1
	3	Coma with Vertical Gaze Palsy: Rel- evance of Angio-CT in Acute Percheron Artery Syndrome 显示文摘	Godani M Auci A Torri T	2010	Case Reports Neurology2010，2，：	1
	4	The Instability of the Adjusted and Unadjusted Environmental Kuznets Curves显示文摘	Auci S Becchetti L	2006	EcologicalEconomics2006，60，1：	1
	5	The instability of the adjusted and unadjusted environmental Kuznets curves显示文摘	Auci S Becchetti L	2006	Ecological Economics2006，60，：	1
	6	The instability of the adjusted and unadjusted environmental Kuznets curves显示文摘	Auci S Becchetti L	2006	Ecological Economics2006，，60：	1
	7	The instability of the adjusted and unadjusted environmental Kuznets curves显示文摘	Sabrina Auci Leonardo Becchetti	2006	Ecological Economics2006，，1：	1
	8	HE3286:A novel synthetic steroid as an oral treatment for autoimmune disease显示文摘	C Ahlem D Auci K Mangano		0，，：	1
	9	lgE against HIV proteins in clinically healthy children with H1V disease 显示文摘	Secord EA Kleiner G1 Auci DL	1996	J Allergy Clin Immunol1996，98，51：	1
	10	Induction of protection against porcine cysticercosis by vaccination with recombinant oncosphere antigens显示文摘	FLISSER A C AUCI C G ZOLI A	2004	Infect Immun2004，72，：	1
	11	Coma with vertical gaze palsy:relevance of angio-CT in acute percheron artery syndrome显示文摘	Godani M Auci A Torri T		0，，02：	1
	12	Oral encapsulated transforming growth factorβ1 reduces endogenous levels:Effect on inflammatory bowel disease显示文摘BACKGROUND TreXTAM®is a combination of the key regulatory cytokine transforming growth factor beta(TGFβ)and all trans retinoic acid(ATRA)microencapsulated for oral delivery to immune structures of the gut.It is in development as a novel treatment for inflammatory bowel disease(IBD).AIM To measure TGFβlevels in blood and tissue after oral administration of encapsulated TGFβ.METHODS Animals were orally administered encapsulated TGFβby gavage.Levels of drug substance in blood and in gut tissues at various times after administration were measured by ELISA.RESULTS We made the surprising discovery that oral administration of TreXTAM dramatically(approximately 50%)and significantly(P=0.025)reduced TGFβlevels in colon,but not small intestine or mesenteric lymph nodes.Similarly,levels in rat serum after 25 d of thrice weekly dosing with either TreXTAM,or microencapsulated TGFβalone(denoted as TPX6001)were significantly(P<0.01)reduced from baseline levels.When tested in the SCID mouse CD4+CD25-adoptive cell transfer(ACT)model of IBD,oral TPX6001 alone provided only a transient benefit in terms of reduced weight loss.CONCLUSION These observations suggest a negative feedback mechanism in the gut whereby local delivery of TGFβresults in reduced local and systemic levels of the active form of TGFβ.Our findings suggest potential clinical implications for use of encapsulated TGFβ,perhaps in the context of IBD and/or other instances of fibrosis and/or pathological TGFβsignaling.	Laura Hammer Stacia Furtado Edith Mathiowitz Dominick L Auci	2020	World Journal of Gastrointestinal Pharmacology and Therapeutics2020，11，5：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费